Dr. Kalluri’s research is broadly interested in the study of cell and tissue microenvironment and its impact on cancer progression and metastasis. Kalluri received his Ph.D. in Biochemistry and Molecular Biology from the University of Kansas Medical Center and his M.D. from Brown University Medical School. In 1997 he moved to Harvard Medical School as assistant professor of medicine and as a faculty based in the Department of Medicine at the Beth Israel Deaconess Medical Center. He later was appointed the chief of the Division of Matrix Biology and promoted to professor of medicine at Harvard Medical School. In 2012 Dr. Kalluri moved to The University of Texas MD Anderson Cancer Center as Professor and Chairman of the Department of Cancer Biology and Director of the Metastasis Research Center, and he currently holds the RE Bob Smith Distinguished Chair for Cancer Research.
Blood/liquid biopsy-based biomarkers for the most accurate early detection of cancer are still in the early phases of development. Before these types of biomarkers/tests can be used in the clinical setting, various clinical and preclinical issues (e.g. detection sensitivity) need to be addressed. This session discusses latest advancements in the development of blood-based biomarkers and describes clinical study programs in which they are implemented, including the limitations and challenges that need to be overcome before the translation of their use for clinical purpose will be a reality.